LONDON, Sept. 3, 2015 /PRNewswire/ -- With a population of more than 1 billion, China is the world's largest country and therefore also its single largest potential market for goods and services. In the past ten years, China has led all major world economies in the average rate of growth in real GDP, total health expenditures, and government health expenditures. As an in vitro diagnostics (IVD) market, China trails only the populous, developed markets of the United States, western European countries, and Japan. China represents one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest growing among the top ten IVD country markets. This report places China and its IVD market in context with the developing world in terms of diseases, economic and healthcare system development, and other key metrics related to health expenditures and diagnostics. China as an IVD market opportunity is defined by its standing next to other populous countries with demonstrated economic promise for over the past decade - Brazil, Russia and India; collectively with China referred to as "BRIC"ť nations. China and its healthcare system are confronted by challenges shared by less developed countries, but also burdens common among developed middle-income and affluent countries such as diabetes, cardiovascular disease, obesity and diseases of aging.
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY Exhibit 1-1: Global Map of China Exhibit 1-2: Industrial Map of China Table 1-1: BRIC IVD Markets by Country, 2014-2019 Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD - CHINA IN CONTEXT Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries (2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico,Brazil, China, Russia, United States, France, Japan, World) Table 2-2: Selected Worldwide Disease Statistics, 2014 Exhibit 2-1: Diabetes Population by Country, 2015 Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg,Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States,China) Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015 Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015 Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries Exhibit 2-4: Chinese GDP per Capita by Province, 2012 Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014 Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom, Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland,Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia) Table 2-7: Growth Rates of Government and Total Healthcare Expenditures and Real GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South Korea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy) Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand, Turkey, United Kingdom, United States, Vietnam) Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014 (United States, Japan, Germany, France, Italy, China, Spain, United Kingdom, Brazil, Russia, India) Table 2-10: BRIC IVD Markets by Country, 2014-2019 Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT ANALYSIS Exhibit 3-1: Chinese Hospitals by Tier Exhibit 3-2: Hospital Count by Certification Status, 2014 Exhibit 3-3: Ethnolinguistic Map of China Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria) Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other) Table 4-1: Total IVD Sales in China, 2014-2024 Exhibit 4-2: Total IVD Sales in China, 2014-2024 Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Table 4-5: Immunoassay Sales in China, 2014-2024 Exhibit 4-6: Immunoassay Sales in China, 2014-2024 Table 4-6: Clinical Chemistry Sales in China, 2014-2024 Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024 Table 4-7: Hematology Sales in China, 2014-2024 Exhibit 4-8: Hematology Sales in China, 2014-2024 Table 4-8: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-10: Selected Point of Care/OTC Products Sold in China Table 4-9: Molecular Test Sales in China, 2014-2024 Exhibit 4-11: Molecular Test Sales in China, 2014-2024 Table 4-10: Urinalysis Test Sales in China, 2014-2024 Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024 Table 4-11: Other IVD Test Sales in China, 2014-2024 Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA Table 5-1: Leading Global IVD Companies in China Table 5-2: Leading Domestic IVD Companies in China Table 5-3: Leading Chinese IVD Companies
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY Exhibit 1-1: Global Map of China Exhibit 1-2: Industrial Map of China Table 1-1: BRIC IVD Markets by Country, 2014-2019 Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD -CHINA IN CONTEXT Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries (2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico, Brazil, China, Russia, United States, France, Japan, World) Table 2-2: Selected Worldwide Disease Statistics, 2014 Exhibit 2-1: Diabetes Population by Country, 2015 Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States, China) Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015 Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015 Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries Exhibit 2-4: Chinese GDP per Capita by Province, 2012 Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014 Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom, Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland, Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia) Table 2-7: Growth Rates of Government and Total Healthcare Expenditures andReal GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South Korea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy) Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand, Turkey, United Kingdom, United States, Vietnam) Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014 (United States, Japan, Germany, France, Italy, China, Spain, United Kingdom,Brazil, Russia, India) Table 2-10: BRIC IVD Markets by Country, 2014-2019 Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT ANALYSIS Exhibit 3-1: Chinese Hospitals by Tier Exhibit 3-2: Hospital Count by Certification Status, 2014 Exhibit 3-3: Ethnolinguistic Map of China Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria) Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other) Table 4-1: Total IVD Sales in China, 2014-2024 Exhibit 4-2: Total IVD Sales in China, 2014-2024 Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Table 4-5: Immunoassay Sales in China, 2014-2024 Exhibit 4-6: Immunoassay Sales in China, 2014-2024 Table 4-6: Clinical Chemistry Sales in China, 2014-2024 Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024 Table 4-7: Hematology Sales in China, 2014-2024 Exhibit 4-8: Hematology Sales in China, 2014-2024 Table 4-8: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-10: Selected Point of Care/OTC Products Sold in China Table 4-9: Molecular Test Sales in China, 2014-2024 Exhibit 4-11: Molecular Test Sales in China, 2014-2024 Table 4-10: Urinalysis Test Sales in China, 2014-2024 Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024 Table 4-11: Other IVD Test Sales in China, 2014-2024 Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA Table 5-1: Leading Global IVD Companies in China Table 5-2: Leading Domestic IVD Companies in China Table 5-3: Leading Chinese IVD Companies
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY Exhibit 1-1: Global Map of China Exhibit 1-2: Industrial Map of China Table 1-1: BRIC IVD Markets by Country, 2014-2019 Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD -CHINA IN CONTEXT Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries (2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico,Brazil, China, Russia, United States, France, Japan, World) Table 2-2: Selected Worldwide Disease Statistics, 2014 Exhibit 2-1: Diabetes Population by Country, 2015 Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States, China) Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015 Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015 Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries Exhibit 2-4: Chinese GDP per Capita by Province, 2012 Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014 Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom,Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland,Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia) Table 2-7: Growth Rates of Government and Total Healthcare Expenditures and Real GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, SouthKorea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy) Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy,Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand, Turkey, United Kingdom, United States, Vietnam) Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014 (United States, Japan, Germany, France, Italy, China, Spain, United Kingdom,Brazil, Russia, India) Table 2-10: BRIC IVD Markets by Country, 2014-2019 Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT ANALYSIS Exhibit 3-1: Chinese Hospitals by Tier Exhibit 3-2: Hospital Count by Certification Status, 2014 Exhibit 3-3: Ethnolinguistic Map of China Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria) Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other) Table 4-1: Total IVD Sales in China, 2014-2024 Exhibit 4-2: Total IVD Sales in China, 2014-2024 Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Table 4-5: Immunoassay Sales in China, 2014-2024 Exhibit 4-6: Immunoassay Sales in China, 2014-2024 Table 4-6: Clinical Chemistry Sales in China, 2014-2024 Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024 Table 4-7: Hematology Sales in China, 2014-2024 Exhibit 4-8: Hematology Sales in China, 2014-2024 Table 4-8: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-10: Selected Point of Care/OTC Products Sold in China Table 4-9: Molecular Test Sales in China, 2014-2024 Exhibit 4-11: Molecular Test Sales in China, 2014-2024 Table 4-10: Urinalysis Test Sales in China, 2014-2024 Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024 Table 4-11: Other IVD Test Sales in China, 2014-2024 Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA Table 5-1: Leading Global IVD Companies in China Table 5-2: Leading Domestic IVD Companies in China Table 5-3: Leading Chinese IVD Companies
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Exhibit 1-1: Global Map of China
Exhibit 1-2: Industrial Map of China
Table 1-1: BRIC IVD Markets by Country, 2014-2019
Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD - CHINA IN CONTEXT
Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries (2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico,Brazil, China, Russia, United States, France, Japan, World)
Table 2-2: Selected Worldwide Disease Statistics, 2014
Exhibit 2-1: Diabetes Population by Country, 2015
Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States,China)
Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015
Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015
Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries
Exhibit 2-4: Chinese GDP per Capita by Province, 2012
Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014
Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom,Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland, Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia)
Table 2-7: Growth Rates of Government and Total Healthcare Expenditures andReal GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South Korea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy)
Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand, Turkey, United Kingdom, United States, Vietnam)
Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014 (United States, Japan, Germany, France, Italy, China, Spain, United Kingdom,Brazil, Russia, India)
Table 2-10: BRIC IVD Markets by Country, 2014-2019
Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT ANALYSIS
Exhibit 3-1: Chinese Hospitals by Tier
Exhibit 3-2: Hospital Count by Certification Status, 2014
Exhibit 3-3: Ethnolinguistic Map of China
Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria)
Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE
Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other)
Table 4-1: Total IVD Sales in China, 2014-2024
Exhibit 4-2: Total IVD Sales in China, 2014-2024
Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Table 4-5: Immunoassay Sales in China, 2014-2024
Exhibit 4-6: Immunoassay Sales in China, 2014-2024
Table 4-6: Clinical Chemistry Sales in China, 2014-2024
Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024
Table 4-7: Hematology Sales in China, 2014-2024
Exhibit 4-8: Hematology Sales in China, 2014-2024
Table 4-8: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-10: Selected Point of Care/OTC Products Sold in China
Table 4-9: Molecular Test Sales in China, 2014-2024
Exhibit 4-11: Molecular Test Sales in China, 2014-2024
Table 4-10: Urinalysis Test Sales in China, 2014-2024
Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024
Table 4-11: Other IVD Test Sales in China, 2014-2024
Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA
Table 5-1: Leading Global IVD Companies in China
Table 5-2: Leading Domestic IVD Companies in China
Table 5-3: Leading Chinese IVD Companies
Download the full report: https://www.reportbuyer.com/product/3187706/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
Advertisement
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY Exhibit 1-1: Global Map of China Exhibit 1-2: Industrial Map of China Table 1-1: BRIC IVD Markets by Country, 2014-2019 Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014
Advertisement
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD - CHINA IN CONTEXT Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries (2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico,Brazil, China, Russia, United States, France, Japan, World) Table 2-2: Selected Worldwide Disease Statistics, 2014 Exhibit 2-1: Diabetes Population by Country, 2015 Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg,Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States,China) Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015 Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015 Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries Exhibit 2-4: Chinese GDP per Capita by Province, 2012 Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014 Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom, Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland,Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia) Table 2-7: Growth Rates of Government and Total Healthcare Expenditures and Real GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South Korea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy) Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand, Turkey, United Kingdom, United States, Vietnam) Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014 (United States, Japan, Germany, France, Italy, China, Spain, United Kingdom, Brazil, Russia, India) Table 2-10: BRIC IVD Markets by Country, 2014-2019 Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT ANALYSIS Exhibit 3-1: Chinese Hospitals by Tier Exhibit 3-2: Hospital Count by Certification Status, 2014 Exhibit 3-3: Ethnolinguistic Map of China Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria) Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other) Table 4-1: Total IVD Sales in China, 2014-2024 Exhibit 4-2: Total IVD Sales in China, 2014-2024 Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Table 4-5: Immunoassay Sales in China, 2014-2024 Exhibit 4-6: Immunoassay Sales in China, 2014-2024 Table 4-6: Clinical Chemistry Sales in China, 2014-2024 Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024 Table 4-7: Hematology Sales in China, 2014-2024 Exhibit 4-8: Hematology Sales in China, 2014-2024 Table 4-8: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-10: Selected Point of Care/OTC Products Sold in China Table 4-9: Molecular Test Sales in China, 2014-2024 Exhibit 4-11: Molecular Test Sales in China, 2014-2024 Table 4-10: Urinalysis Test Sales in China, 2014-2024 Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024 Table 4-11: Other IVD Test Sales in China, 2014-2024 Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA Table 5-1: Leading Global IVD Companies in China Table 5-2: Leading Domestic IVD Companies in China Table 5-3: Leading Chinese IVD Companies
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY Exhibit 1-1: Global Map of China Exhibit 1-2: Industrial Map of China Table 1-1: BRIC IVD Markets by Country, 2014-2019 Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD -CHINA IN CONTEXT Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries (2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico, Brazil, China, Russia, United States, France, Japan, World) Table 2-2: Selected Worldwide Disease Statistics, 2014 Exhibit 2-1: Diabetes Population by Country, 2015 Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States, China) Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015 Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015 Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries Exhibit 2-4: Chinese GDP per Capita by Province, 2012 Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014 Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom, Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland, Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia) Table 2-7: Growth Rates of Government and Total Healthcare Expenditures andReal GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South Korea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy) Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand, Turkey, United Kingdom, United States, Vietnam) Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014 (United States, Japan, Germany, France, Italy, China, Spain, United Kingdom,Brazil, Russia, India) Table 2-10: BRIC IVD Markets by Country, 2014-2019 Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT ANALYSIS Exhibit 3-1: Chinese Hospitals by Tier Exhibit 3-2: Hospital Count by Certification Status, 2014 Exhibit 3-3: Ethnolinguistic Map of China Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria) Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other) Table 4-1: Total IVD Sales in China, 2014-2024 Exhibit 4-2: Total IVD Sales in China, 2014-2024 Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Table 4-5: Immunoassay Sales in China, 2014-2024 Exhibit 4-6: Immunoassay Sales in China, 2014-2024 Table 4-6: Clinical Chemistry Sales in China, 2014-2024 Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024 Table 4-7: Hematology Sales in China, 2014-2024 Exhibit 4-8: Hematology Sales in China, 2014-2024 Table 4-8: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-10: Selected Point of Care/OTC Products Sold in China Table 4-9: Molecular Test Sales in China, 2014-2024 Exhibit 4-11: Molecular Test Sales in China, 2014-2024 Table 4-10: Urinalysis Test Sales in China, 2014-2024 Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024 Table 4-11: Other IVD Test Sales in China, 2014-2024 Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA Table 5-1: Leading Global IVD Companies in China Table 5-2: Leading Domestic IVD Companies in China Table 5-3: Leading Chinese IVD Companies
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY Exhibit 1-1: Global Map of China Exhibit 1-2: Industrial Map of China Table 1-1: BRIC IVD Markets by Country, 2014-2019 Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD -CHINA IN CONTEXT Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries (2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico,Brazil, China, Russia, United States, France, Japan, World) Table 2-2: Selected Worldwide Disease Statistics, 2014 Exhibit 2-1: Diabetes Population by Country, 2015 Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States, China) Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015 Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015 Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries Exhibit 2-4: Chinese GDP per Capita by Province, 2012 Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014 Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom,Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland,Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia) Table 2-7: Growth Rates of Government and Total Healthcare Expenditures and Real GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, SouthKorea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy) Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy,Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand, Turkey, United Kingdom, United States, Vietnam) Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014 (United States, Japan, Germany, France, Italy, China, Spain, United Kingdom,Brazil, Russia, India) Table 2-10: BRIC IVD Markets by Country, 2014-2019 Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT ANALYSIS Exhibit 3-1: Chinese Hospitals by Tier Exhibit 3-2: Hospital Count by Certification Status, 2014 Exhibit 3-3: Ethnolinguistic Map of China Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria) Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other) Table 4-1: Total IVD Sales in China, 2014-2024 Exhibit 4-2: Total IVD Sales in China, 2014-2024 Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%) Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%) Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%) Table 4-5: Immunoassay Sales in China, 2014-2024 Exhibit 4-6: Immunoassay Sales in China, 2014-2024 Table 4-6: Clinical Chemistry Sales in China, 2014-2024 Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024 Table 4-7: Hematology Sales in China, 2014-2024 Exhibit 4-8: Hematology Sales in China, 2014-2024 Table 4-8: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024 Exhibit 4-10: Selected Point of Care/OTC Products Sold in China Table 4-9: Molecular Test Sales in China, 2014-2024 Exhibit 4-11: Molecular Test Sales in China, 2014-2024 Table 4-10: Urinalysis Test Sales in China, 2014-2024 Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024 Table 4-11: Other IVD Test Sales in China, 2014-2024 Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA Table 5-1: Leading Global IVD Companies in China Table 5-2: Leading Domestic IVD Companies in China Table 5-3: Leading Chinese IVD Companies
LIST OF EXHIBITS
ONE: EXECUTIVE SUMMARY
Exhibit 1-1: Global Map of China
Exhibit 1-2: Industrial Map of China
Table 1-1: BRIC IVD Markets by Country, 2014-2019
Table 1-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014
TWO: INTRODUCTION TO HEALTH CARE AND DIAGNOSTICS IN THE DEVELOPING WORLD - CHINA IN CONTEXT
Table 2-1: Elderly Support Ratio in China, Other BRIC and Selected Countries (2010/2050) (Niger, Uganda, Pakistan, India, Egypt, Guatemala, Morocco, Mexico,Brazil, China, Russia, United States, France, Japan, World)
Table 2-2: Selected Worldwide Disease Statistics, 2014
Exhibit 2-1: Diabetes Population by Country, 2015
Exhibit 2-2: Cancer Prevalance by Country, 2015 (Australia, Austria, Belgium,Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States,China)
Exhibit 2-3: Cardiovascular Disease Death as a Percentage of Total Deaths, 2015
Table 2-3: Types of IVD and Clinical Laboratory Tests, 2015
Table 2-4: Clinical Lab Counts and Lab Automation Penetration in BRIC Countries
Exhibit 2-4: Chinese GDP per Capita by Province, 2012
Exhibit 2-5: Venture Capital Funding in China, 2006 - 2014
Table 2-6: Government and Total Health Expenditures in BRIC and Comparison Countries (United States, France, Germany, Italy, Japan, United Kingdom,Australia, Brazil, South Africa, Argentina, South Korea, Vietnam, Poland, Turkey, Mexico, Russia, Nigeria, China, Thailand, India, Indonesia)
Table 2-7: Growth Rates of Government and Total Healthcare Expenditures andReal GDP (BRIC and Comparison Countries; 2003-2013) (China, India, Nigeria,Argentina, Vietnam, Indonesia, Turkey, Russia, Poland, Thailand, Brazil, South Korea, South Africa, Australia, Mexico, United States, Germany, United Kingdom, France, Japan, Italy)
Table 2-8: Healthcare System Capacities - BRIC and Comparison Countries (Argentina, Australia, Brazil, China, France, Germany, India, Indonesia, Italy, Japan, South Korea, Mexico, Nigeria, Poland, Russia, South Africa, Thailand, Turkey, United Kingdom, United States, Vietnam)
Table 2-9: Per Capita IVD Expenditures and IVD Markets by Country, 2014 (United States, Japan, Germany, France, Italy, China, Spain, United Kingdom,Brazil, Russia, India)
Table 2-10: BRIC IVD Markets by Country, 2014-2019
Table 2-11: Selected Made-in-China Lab Supplies
THREE: CHINA IVD SWOT ANALYSIS
Exhibit 3-1: Chinese Hospitals by Tier
Exhibit 3-2: Hospital Count by Certification Status, 2014
Exhibit 3-3: Ethnolinguistic Map of China
Table 3-1: Out-Of-Pocket, Other Private and Government Healthcare Expenditures in BRIC and Comparison Countries (%) (South Africa, France, United Kingdom, United States, Germany, Thailand, Turkey, Japan, Australia, Italy, Poland, Argentina, Brazil, South Korea, China, Russia, Mexico, Indonesia, Vietnam, India, Nigeria)
Exhibit 3-4: Chinese Urban Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
Exhibit 3-5: Chinese Rural Healthcare Market by National Market Shares of Province/Direct-Controlled Municipality
FOUR: CHINA IVD MARKET SIZE
Exhibit 4-1: Global IVD and Clinical Lab Market, 2014 (United States, Western Europe, Japan, Eastern Europe, China, India, Russia, Brazil, Other)
Table 4-1: Total IVD Sales in China, 2014-2024
Exhibit 4-2: Total IVD Sales in China, 2014-2024
Table 4-2: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Exhibit 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2014 (%)
Table 4-3: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Exhibit 4-4: IVD Sales in China by Market Segment (Immunoassays, Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2019 (%)
Table 4-4: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Exhibit 4-5: IVD Sales in China by Market Segment (Immunoassays,Clinical Chemistry, Hematology, POC/OTC, Molecular, Urinalysis, Other) in 2024 (%)
Table 4-5: Immunoassay Sales in China, 2014-2024
Exhibit 4-6: Immunoassay Sales in China, 2014-2024
Table 4-6: Clinical Chemistry Sales in China, 2014-2024
Exhibit 4-7: Clinical Chemistry Sales in China, 2014-2024
Table 4-7: Hematology Sales in China, 2014-2024
Exhibit 4-8: Hematology Sales in China, 2014-2024
Table 4-8: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-9: Point of Care/OTC Sales in China, 2014-2024
Exhibit 4-10: Selected Point of Care/OTC Products Sold in China
Table 4-9: Molecular Test Sales in China, 2014-2024
Exhibit 4-11: Molecular Test Sales in China, 2014-2024
Table 4-10: Urinalysis Test Sales in China, 2014-2024
Exhibit 4-12: Urinalysis Test Sales in China, 2014-2024
Table 4-11: Other IVD Test Sales in China, 2014-2024
Exhibit 4-13: Other IVD Test Sales in China, 2014-2024
FIVE: INDUSTRY AND COMPANY ACTIVITY IN CHINA
Table 5-1: Leading Global IVD Companies in China
Table 5-2: Leading Domestic IVD Companies in China
Table 5-3: Leading Chinese IVD Companies
Download the full report: https://www.reportbuyer.com/product/3187706/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ivd-in-china-300138078.html
SOURCE ReportBuyer
